WHO Reports Low Efficacy Of Coronavirus Medicine

WHO Reports Low Efficacy Of Coronavirus Medicine
WHO Reports Low Efficacy Of Coronavirus Medicine

Video: WHO Reports Low Efficacy Of Coronavirus Medicine

Отличия серверных жестких дисков от десктопных
Video: China considering mixing different COVID-19 vaccines to improve low efficacy of its Vaccines | WION 2023, January

WHO reports low efficacy of coronavirus medicine

The study found that the experimental drug used to treat Donald Trump did not increase the chances of surviving COVID-19 patients. WHO reported in July that remdesivir reduces the likelihood of hospitalization

Photo: Ted S. Warren / AP

Treatment of coronavirus infection with the experimental drug remdesivir does not significantly affect patient mortality. This is evidenced by clinical studies of the World Health Organization, writes the Financial Times.

WHO investigated the course of treatment of 11.2 thousand patients with coronavirus and concluded that none of the drugs affected the patient's chances of survival and did not reduce the need for mechanical ventilation.

We are talking not only about remdesivir, but also about the drugs hydroxychloroquine, lopinavir and interferon. In addition, a WHO study has shown that these drugs have little to no effect on the length of time a COVID-19 patient stays in the hospital.

Trump's doctor spoke about the beginning of the president's treatment with remdesivir


Remdesivir was originally developed by the American pharmaceutical company Gilead Sciences as a treatment for Ebola. After testing in April, it received approval for use in COVID-19 in the United States and the European Union. The US National Institutes of Health reported that remdesivir shortened treatment time from an average of 15 to 11 days. Gilead Sciences published data in July that the drug could reduce the likelihood of death from coronavirus. However, this information was not confirmed by a control study.

"The emerging data seems to be inconsistent with the more robust evidence from numerous randomized controlled trials supporting the clinical benefit of remdesivir," Gilead Sciences said in response to a WHO statement.

WHO called "encouraging" drug against COVID-19


Read on RBC Pro

Cheap strategy: how the famous discounter Lidl conquered Europe

“Robbery in broad daylight”: how students' requests have changed MB- Bloomberg

How businessmen in Russia are personally liable for the debts of the firms they control

Lamod CEO Jerry Calmees - RBC Pro: "Traditional trade no longer exists"

In October, several European countries, including the United Kingdom, ordered 500,000 courses of remdesivir from a pharmaceutical company to treat patients with COVID-19. The cost of one five-day course of the drug is $ 2340.

American President Donald Trump, who was ill with coronavirus infection, was treated with remdesivir. After that, the head of state promised the residents of the country the same treatment that he himself received, on a free basis.

In July, the WHO reported that remdesevir is showing "encouraging" results: in particular, it has reduced hospitalizations, but has not led to a decrease in deaths from coronavirus. In September, the Russian Ministry of Health recommended remdesivir among six drugs for the treatment of COVID-19.

How the number of people who recovered and died from coronavirus is changing in the world

Recovered (new cases)

Deceased (new cases)

Source: JHU

World data i

Author Mikhail Kotlyar UNIQA NEWS


Popular by topic